Steroid 17-alpha-Hydroxylase
"Steroid 17-alpha-Hydroxylase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.
| Descriptor ID |
D013254
|
| MeSH Number(s) |
D08.244.453.487.500 D08.244.453.915.748 D08.811.682.690.708.170.444.500 D08.811.682.690.708.170.915.748 D12.776.422.220.453.487.500 D12.776.422.220.453.915.748
|
| Concept/Terms |
Steroid 17-alpha-Hydroxylase- Steroid 17-alpha-Hydroxylase
- 17-alpha-Hydroxylase, Steroid
- Steroid 17 alpha-Hydroxylase
- 17 alpha-Hydroxylase, Steroid
- Steroid 17 alpha Hydroxylase
- Steroid-17-Hydroxylase
- Steroid 17 Hydroxylase
- Steroid 17-Hydroxylase
- 17-Hydroxylase, Steroid
- Steroid 17-Monooxygenase
- 17-Monooxygenase, Steroid
- Steroid 17 Monooxygenase
- 17,20-Desmolase
- 17,20 Desmolase
- 17,20-Lyase
- 17,20 Lyase
- Cytochrome P450(17 alpha)
- Steroid 17 alpha-Monooxygenase
- 17 alpha-Monooxygenase, Steroid
- Steroid 17 alpha Monooxygenase
- alpha-Monooxygenase, Steroid 17
- CYP17
- 17 alpha-Hydroxylase
- 17 alpha Hydroxylase
- P450(c17)
- Cytochrome P-450(17-alpha)
- 17 alpha-Hydroxylase Cytochrome P-450
- 17 alpha Hydroxylase Cytochrome P 450
- Cytochrome P-450(17 alpha)
17 alpha-Hydroxyprogesterone Aldolase- 17 alpha-Hydroxyprogesterone Aldolase
- 17 alpha Hydroxyprogesterone Aldolase
- Aldolase, 17 alpha-Hydroxyprogesterone
- alpha-Hydroxyprogesterone Aldolase, 17
- Hydroxyprogesterone Aldolase
- Aldolase, Hydroxyprogesterone
|
Below are MeSH descriptors whose meaning is more general than "Steroid 17-alpha-Hydroxylase".
Below are MeSH descriptors whose meaning is more specific than "Steroid 17-alpha-Hydroxylase".
This graph shows the total number of publications written about "Steroid 17-alpha-Hydroxylase" by people in this website by year, and whether "Steroid 17-alpha-Hydroxylase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Steroid 17-alpha-Hydroxylase" by people in Profiles.
-
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 10 01; 40(28):3301-3309.
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest. 2017 Jun 01; 127(6):2326-2338.
-
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354.
-
Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer. 2016 Mar 01; 138(5):1146-52.
-
Genetics of premature ovarian failure. Curr Opin Obstet Gynecol. 2015 Jun; 27(3):167-74.
-
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48.
-
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015 Mar; 95:80-7.
-
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
-
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014 Aug 15; 20(16):4218-27.
-
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60.